saniona.comCrawled Oct 29, 2026
The company collaborates with patients, caregivers, and advocacy groups to align its work with core values.
SAN2219 is a subtype-selective GABAA receptor modulator designed to control seizures without adverse effects by reducing excessive neuronal activation.
SAN2465 is a rapid-acting antidepressant targeting GABAA α5 receptors, distinct from conventional antidepressants and psychedelic drugs.
Recent publications and presentations.
The page lists a December 2024 publication on epilepsy-associated GABAA receptor variants, authored by researchers including Kan ASH and Møller RS, published in *Proc Natl Acad Sci U S*.
The page highlights interviews, including CEO Thomas Feldthus presenting at Redeye’s Neurology 2026 event and Q1/Q2 2026 updates.
The page lists recent news, including Saniona’s Q1 2026 presentation by CEO Thomas Feldthus and CFO Johnny Stilou.
The page lists press releases, including Q1/Q2 2026 earnings presentations and a 2023 collaboration announcement with AstronauTx.
JOIN US Openings Current Openings Current openings, please see below. This page requires javascript
Saniona’s small team aims to make a significant impact on rare disease patients and caregivers.
Saniona’s small team focuses on advancing treatments for patients and caregivers affected by rare diseases.
The page names John Haurum as chairman of the board in 2025.
The page details compensation for senior executives in 2023, approved at an extraordinary shareholders’ meeting on May 29, 2024.
Saniona aims to improve lives of rare disease patients through scientific innovation, with its lead product candidate, Tesomet, in mid-stage clinical trials for two rare diseases.
Saniona was built on a foundation of more than 20 years of pioneering ion channel research.
Robust ion channel drug discovery engine. Saniona is a leader in the discovery of highly specific ion channel modulators. Ion channel modulation is a validated approach to treating disease and has been used in medicines for diabetes, hypertension, epilepsy and more.
Saniona’s focus is on the discovery, development and delivery of proprietary product candidates for the treatment of rare diseases with high unmet medical need.
Improving the lives of rare disease patients around the world through scientific innovation
